J&J Covid vaccine moderately effective, less against S. Africa variant

Washington (AFP) – Johnson & Johnson’s single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced Friday, following results from a phase 3 trial of almost 44,000 people across many countries. The figure however was as high as 72 percent in the United States but went down to 57 percent in South Africa, where a more transmissible variant is dominant. The company added that the vaccine was 85 percent effective in preventing severe Covid-19 across all geographical regions. “We’re proud to have reached this critical milestone and our commitment to address this global …

Read More

HEDGE accordingly